Alexey Bersenev, MD, PhD
Laboratory Medicine
Titles
- Assistant Professor of Laboratory Medicine
Education & Training
- PhDInstitute of Transplantology and Artificial Organs (2003)
- MDIzhevsk State Medical Academy (2000)
Additional Information
Publications
- Gustafson MP, Ligon JA, Bersenev A, McCann CD, Shah NN, Hanley PJ. Emerging frontiers in immuno- and gene therapy for cancer. Cytotherapy 2022, 25: 20-32. PMID: 36280438, PMCID: PMC9790040, DOI: 10.1016/j.jcyt.2022.10.002.
- Ye L, Park JJ, Peng L, Yang Q, Chow RD, Dong MB, Lam SZ, Guo J, Tang E, Zhang Y, Wang G, Dai X, Du Y, Kim HR, Cao H, Errami Y, Clark P, Bersenev A, Montgomery RR, Chen S. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metabolism 2022, 34: 595-614.e14. PMID: 35276062, PMCID: PMC8986623, DOI: 10.1016/j.cmet.2022.02.009.
- Bersenev A, Gustafson MP, Hanley PJ. ISCT survey on hospital practices to support externally manufactured investigational cell-gene therapy products. Cytotherapy 2021, 24: 27-31. PMID: 34810083, DOI: 10.1016/j.jcyt.2021.09.009.
- Hanley PJ, Bersenev A, Gustafson MP. Delivering externally manufactured cell and gene therapy products to patients: perspectives from the academic center experience. Cytotherapy 2021, 24: 16-18. PMID: 34753676, DOI: 10.1016/j.jcyt.2021.09.010.
- Couto P, Rotondi M, Bersenev A, Hewitt C, Nienow A, Verter F, Rafiq Q. Expansion of human mesenchymal stem/stromal cells (hMSCs) in bioreactors using microcarriers: lessons learnt and what the future holds. Biotechnology Advances 2020, 45: 107636. PMID: 32980437, DOI: 10.1016/j.biotechadv.2020.107636.
- Hood T, Bersenev A, Smith D, Heathman T, Rafiq Q. Analysis of the clinical landscape for genetically-modified cellular immunotherapies highlights the need for optimized and consistent manufacturing processes. Cytotherapy 2020, 22: s36. DOI: 10.1016/j.jcyt.2020.03.028.
- Couto P, Bersenev A, Rafiq Q. Chapter 2 Process development and manufacturing approaches for mesenchymal stem cell therapies. 2020, 33-71. DOI: 10.1016/b978-0-12-816221-7.00002-1.
- Gehrie E, Bersenev A, Bruscia E, Krause D, Schulz W. Gene therapy applications to transfusion medicine. 2016, 452-455. DOI: 10.1002/9781119013020.ch38.
- Levine B, Svoboda J, Nasta S, Porter D, Chong E, Lacey S, Mahnke Y, Melenhorst J, Chew A, Shah G, Hasskar J, Wasik M, Landsburg D, Mato A, Garfall A, Frey N, Shaw P, Marcucci K, Shea J, McConville H, Manvar N, O'Rourke M, Lamontagne A, Bersenev A, Zheng Z, Schuster S, June C. Chimeric antigen receptor modified T cells directed against CD19 (CTL019) induce clinical responses in patients with relapsed or refractory CD19+ lymphomas. Cytotherapy 2015, 17: s13. DOI: 10.1016/j.jcyt.2015.03.327.
- Balcerek J, Jiang J, Bersenev A, Song Y, Wu C, Tong W. 14-3-3 Regulates the Lnk/JAK2 Pathway In Hematopoietic Stem and Progenitor Cells. Blood 2010, 116: 86. DOI: 10.1182/blood.v116.21.86.86.
- Bersenev A, Wu C, Balcerek J, Tong W. Lnk Constrains Oncogenic JAK2-Induced Myeloproliferative Disease in Mice. Blood 2009, 114: 1437. DOI: 10.1182/blood.v114.22.1437.1437.
- Gregory G, Miccio A, Bersenev A, Wang Y, Hong W, Zhang Z, Poncz M, Tong W, Blobel G. FOG-1 Requires NuRD to Promote Hematopoiesis and Maintain Lineage Fidelity within the Megakaryocytic–Erythroid Compartment. Blood 2009, 114: 702. DOI: 10.1182/blood.v114.22.702.702.
- Bersenev A, Wu C, Balcerek J, Tong W. Lnk Controls Hematopoietic Stem Cell Self-Renewal through Direct Interactions with JAK2 and Contributes to Oncogenic JAK2-Induced Myeloproliferative Diseases in Mice. Blood 2008, 112: 895. DOI: 10.1182/blood.v112.11.895.895.
- Gregory G, Wang Y, Hong W, Miccio A, Bersenev A, Yu X, Wang H, Choi J, Shelat S, Tong W, Poncz M, Blobel G. The GATA-1 Cofactor FOG-1 Recruits NuRD to Promote Normal Erythroid and Megakaryocyte Development and Maintain Lineage Fidelity by Restricting Mast Cell Gene Expression. Blood 2008, 112: 1373. DOI: 10.1182/blood.v112.11.1373.1373.
Departments and Programs
Titles
- Assistant Professor of Laboratory Medicine
Education & Training
- PhDInstitute of Transplantology and Artificial Organs (2003)
- MDIzhevsk State Medical Academy (2000)
Additional Information
Publications
- Gustafson MP, Ligon JA, Bersenev A, McCann CD, Shah NN, Hanley PJ. Emerging frontiers in immuno- and gene therapy for cancer. Cytotherapy 2022, 25: 20-32. PMID: 36280438, PMCID: PMC9790040, DOI: 10.1016/j.jcyt.2022.10.002.
- Ye L, Park JJ, Peng L, Yang Q, Chow RD, Dong MB, Lam SZ, Guo J, Tang E, Zhang Y, Wang G, Dai X, Du Y, Kim HR, Cao H, Errami Y, Clark P, Bersenev A, Montgomery RR, Chen S. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metabolism 2022, 34: 595-614.e14. PMID: 35276062, PMCID: PMC8986623, DOI: 10.1016/j.cmet.2022.02.009.
- Bersenev A, Gustafson MP, Hanley PJ. ISCT survey on hospital practices to support externally manufactured investigational cell-gene therapy products. Cytotherapy 2021, 24: 27-31. PMID: 34810083, DOI: 10.1016/j.jcyt.2021.09.009.
- Hanley PJ, Bersenev A, Gustafson MP. Delivering externally manufactured cell and gene therapy products to patients: perspectives from the academic center experience. Cytotherapy 2021, 24: 16-18. PMID: 34753676, DOI: 10.1016/j.jcyt.2021.09.010.
- Couto P, Rotondi M, Bersenev A, Hewitt C, Nienow A, Verter F, Rafiq Q. Expansion of human mesenchymal stem/stromal cells (hMSCs) in bioreactors using microcarriers: lessons learnt and what the future holds. Biotechnology Advances 2020, 45: 107636. PMID: 32980437, DOI: 10.1016/j.biotechadv.2020.107636.
- Hood T, Bersenev A, Smith D, Heathman T, Rafiq Q. Analysis of the clinical landscape for genetically-modified cellular immunotherapies highlights the need for optimized and consistent manufacturing processes. Cytotherapy 2020, 22: s36. DOI: 10.1016/j.jcyt.2020.03.028.
- Couto P, Bersenev A, Rafiq Q. Chapter 2 Process development and manufacturing approaches for mesenchymal stem cell therapies. 2020, 33-71. DOI: 10.1016/b978-0-12-816221-7.00002-1.
- Gehrie E, Bersenev A, Bruscia E, Krause D, Schulz W. Gene therapy applications to transfusion medicine. 2016, 452-455. DOI: 10.1002/9781119013020.ch38.
- Levine B, Svoboda J, Nasta S, Porter D, Chong E, Lacey S, Mahnke Y, Melenhorst J, Chew A, Shah G, Hasskar J, Wasik M, Landsburg D, Mato A, Garfall A, Frey N, Shaw P, Marcucci K, Shea J, McConville H, Manvar N, O'Rourke M, Lamontagne A, Bersenev A, Zheng Z, Schuster S, June C. Chimeric antigen receptor modified T cells directed against CD19 (CTL019) induce clinical responses in patients with relapsed or refractory CD19+ lymphomas. Cytotherapy 2015, 17: s13. DOI: 10.1016/j.jcyt.2015.03.327.
- Balcerek J, Jiang J, Bersenev A, Song Y, Wu C, Tong W. 14-3-3 Regulates the Lnk/JAK2 Pathway In Hematopoietic Stem and Progenitor Cells. Blood 2010, 116: 86. DOI: 10.1182/blood.v116.21.86.86.
- Bersenev A, Wu C, Balcerek J, Tong W. Lnk Constrains Oncogenic JAK2-Induced Myeloproliferative Disease in Mice. Blood 2009, 114: 1437. DOI: 10.1182/blood.v114.22.1437.1437.
- Gregory G, Miccio A, Bersenev A, Wang Y, Hong W, Zhang Z, Poncz M, Tong W, Blobel G. FOG-1 Requires NuRD to Promote Hematopoiesis and Maintain Lineage Fidelity within the Megakaryocytic–Erythroid Compartment. Blood 2009, 114: 702. DOI: 10.1182/blood.v114.22.702.702.
- Bersenev A, Wu C, Balcerek J, Tong W. Lnk Controls Hematopoietic Stem Cell Self-Renewal through Direct Interactions with JAK2 and Contributes to Oncogenic JAK2-Induced Myeloproliferative Diseases in Mice. Blood 2008, 112: 895. DOI: 10.1182/blood.v112.11.895.895.
- Gregory G, Wang Y, Hong W, Miccio A, Bersenev A, Yu X, Wang H, Choi J, Shelat S, Tong W, Poncz M, Blobel G. The GATA-1 Cofactor FOG-1 Recruits NuRD to Promote Normal Erythroid and Megakaryocyte Development and Maintain Lineage Fidelity by Restricting Mast Cell Gene Expression. Blood 2008, 112: 1373. DOI: 10.1182/blood.v112.11.1373.1373.
Departments and Programs